Alerts will be sent to your verified email
Verify EmailPFIZER
|
Pfizer
|
Natco Pharma
|
Astrazeneca Pharma I
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
5.2 % | 31.2 % | 18.6 % |
|
Financials
|
|||
|
5 yr Average ROE
|
19.03 % | 15.58 % | 17.42 % |
|
5yr average Equity Multiplier
|
1.25 | 1.17 | 1.99 |
|
5yr Average Asset Turnover Ratio
|
0.6 | 0.48 | 0.91 |
|
5yr Avg Net Profit Margin
|
26.04 % | 26.79 % | 9.65 % |
|
Price to Book
|
5.15 | 2.45 | 26.0 |
|
P/E
|
25.35 | 13.59 | 103.39 |
|
5yr Avg Cash Conversion Cycle
|
21.86 Days | 4.27 Days | -6.33 Days |
|
Inventory Days
|
49.93 Days | 91.91 Days | 68.19 Days |
|
Days Receivable
|
29.1 Days | 93.3 Days | 35.81 Days |
|
Days Payable
|
77.28 Days | 134.54 Days | 187.52 Days |
|
5yr Average Interest Coverage Ratio
|
185.18 | 60.49 | 142.38 |
|
5yr Avg ROCE
|
23.84 % | 19.09 % | 23.84 % |
|
5yr Avg Operating Profit Margin
|
31.72 % | 34.0 % | 14.57 % |
|
5 yr average Debt to Equity
|
0.0 | 0.06 | 0.0 |
|
5yr CAGR Net Profit
|
76.68 % | 33.73 % | 4.4 % |
|
5yr Average Return on Assets
|
15.25 % | 13.46 % | 8.92 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
63.92 % | 49.42 % | 75.0 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.58 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
5.56 % | -6.78 % | 4.44 % |
|
Pfizer
|
Natco Pharma
|
Astrazeneca Pharma I
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|